Metrics as of 10/16/2026, 02:14 AM (Berlin time), refresh in progress.
Eton Pharmaceuticals Stock
Eton Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Sean E. Brynjelsen
- Employees
- 44
- Market cap
- $1.5 B
- IPO
- 14/11/2018
Eton Pharmaceuticals, Inc. is a healthcare company operating in the drug manufacturers, specialty & generic industry. Headquartered in Deer Park, Illinois, the company was incorporated in 2017. Led by CEO Sean E. Brynjelsen, the pharmaceutical firm focuses on developing and commercializing treatments for rare…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Eton Pharmaceuticals stock: price history
1D
-2.9%
1W
-6.2%
1M
-6.6%
6M
+110.1%
YTD
+203.5%
1Y
+168.0%
2Y
+510.3%
5Y
+885.2%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~65% stronger price swings than usual
Eton Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Eton Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of medications for the treatment of rare diseases. The business model is primarily based on the sale of pharmaceutical products as well as the collection of licensing fees for various therapies. The portfolio encompasses treatments for diseases such as adrenal insufficiency, Wilson disease, and phenylketonuria. In addition to its marketed products, the company is in late-stage development of several new drug candidates for chronic conditions such as diabetes mellitus.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Eton Pharmaceuticals
Analyst assessment of Eton Pharmaceuticals
PRICE TARGET LOW
US$68.00
CONSENSUS
US$72.00
MEDIAN
US$70.00
PRICE TARGET HIGH
US$78.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 14/10/2026
Eton Pharmaceuticals stock metrics
P/E
110.39
P/B
30.46
EV/EBITDA
73.65
RETURN ON EQUITY
24.9%
NET MARGIN
30.8%
DEBT/EQUITY
0.62
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.0%
FLOAT SHARES
22,297,989
AVG. DAILY VOLUME (30D)
559,741
Insider transactions (SEC)
Krempa David
Krempa David
MAIER PAUL V
MAIER PAUL V
MAIER PAUL V
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Eton Pharmaceuticals stock
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Sean E. Brynjelsen, the company employs around 44 people.
The IPO was on 14/11/2018; the stock trades on NASDAQ under the ticker ETON.
What do analysts say about Eton Pharmaceuticals stock?
7 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$72.00, ranging from US$68.00 to US$78.00, with a median of US$70.00.
This is an external assessment, not a statement by Market Jury.
When does Eton Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 65% stronger than usual.
Does Eton Pharmaceuticals pay a dividend?
No, Eton Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Eton Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Pacira BioSciences, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Eton Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Eton Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.